

## Supplemental Appendix

1

2

3

4 eTable 1. Type of Prior Oral Anticoagulation..... 2

5 eTable 2A. Association between Randomized Treatment (Apixaban vs. VKA) and Endpoints by Prior Oral Anticoagulant

6 Status (3 Levels)..... 3

7 eTable 2B. Association between Randomized Treatment (Aspirin vs. Placebo) and Endpoints by Prior Oral Anticoagulant

8 Status ..... 5

9

10

11 **eTable 1. Type of Prior Oral Anticoagulation**

Type of OAC	N	Patients on Any Prior OAC (%)	Total Patients Randomized (%)
Warfarin	767	33.9%	16.6%
Rivaroxaban	502	22.2%	10.9%
Apixaban	488	21.6%	10.6%
Dabigatran	265	11.7%	5.7%
Acenocoumarol	220	9.7%	4.8%
Phenprocoumon	74	3.3%	1.6%
Edoxaban	23	1.0%	0.5%
Anticoagulant, not specified	4	0.2%	0.1%

12 Some patients reported multiple types of prior oral anticoagulants.

13 OAC=oral anticoagulant.

14

15 **eTable 2A. Association between Randomized Treatment (Apixaban vs. VKA) and Endpoints by Prior Oral**  
 16 **Anticoagulant Status (3 Levels)**

Endpoint	30 Days				180 Days			Interaction n p-value
	Apixaban KM % (events)	VKA KM % (events)	HR (95% CI) Apixaban vs. VKA	Interaction p-value	Apixaban KM % (events)	VKA KM % (events)	HR (95% CI) Apixaban vs. VKA	
ISTH major/CRNM bleeding				0.3443				0.5710
No prior OAC	4.17 (45)	7.46 (86)	0.558 (0.389– 0.801)		10.87 (113)	15.60 (173)	0.668 (0.527– 0.846)	
Prior NOAC	4.10 (25)	6.15 (35)	0.660 (0.395– 1.103)		10.11 (60)	15.60 (84)	0.626 (0.451– 0.868)	
Prior VKA	4.69 (26)	5.09 (23)	0.917 (0.523– 1.607)		12.60 (67)	15.33 (67)	0.798 (0.569– 1.118)	
ISTH major bleeding				0.6810				0.8400
No prior OAC	1.30 (14)	2.09 (24)	0.626 (0.324– 1.210)		3.04 (31)	5.23 (57)	0.575 (0.371– 0.891)	
Prior NOAC	0.66 (4)	1.59 (9)	0.411 (0.127– 1.335)		3.09 (18)	4.18 (22)	0.701 (0.378– 1.299)	
Prior VKA	1.44 (8)	1.78 (8)	0.815 (0.306– 2.172)		3.74 (20)	5.31 (23)	0.681 (0.376– 1.232)	
Intracranial bleeding				---				0.7502
No prior OAC	0.09 (1)	0.25 (3)	0.363 (0.038– 3.487)		0.30 (3)	0.54 (6)	0.528 (0.132– 2.113)	
Prior NOAC	0.00 (0)	0.00 (0)	---		0.18 (1)	0.58 (3)	0.297 (0.031– 2.857)	
Prior VKA	0.00 (0)	0.00 (0)	---		0.19 (1)	0.96 (4)	0.203 (0.023– 1.820)	
Definite/Probable stent thrombosis				0.3784				0.1927
No prior OAC	0.72 (8)	0.66 (8)	1.106 (0.415– 2.946)		0.91 (10)	0.66 (8)	1.381 (0.545– 3.500)	
Prior NOAC	0.32 (2)	1.00 (6)	0.319 (0.064– 1.581)		0.32 (2)	1.18 (7)	0.273 (0.057– 1.314)	
Prior VKA	0.18 (1)	0.43 (2)	0.408 (0.037– 4.496)		0.36 (2)	0.65 (3)	0.543 (0.091– 3.250)	
All-cause death or rehospitalization				0.2243				0.2970
No prior OAC	9.50 (105)	11.90 (145)	0.798 (0.621– 1.026)		22.87 (247)	27.76 (333)	0.795 (0.675– 0.938)	

Endpoint	30 Days				180 Days			Interaction n p-value
	Apixaban KM % (events)	VKA KM % (events)	HR (95% CI) Apixaban vs. VKA	Interaction p-value	Apixaban KM % (events)	VKA KM % (events)	HR (95% CI) Apixaban vs. VKA	
Prior NOAC	8.66 (54)	11.67 (70)	0.724 (0.507–1.032)		25.03 (154)	30.25 (178)	0.790 (0.637–0.979)	
Prior VKA	8.64 (49)	7.35 (34)	1.166 (0.753–1.806)		24.73 (139)	24.45 (112)	0.991 (0.774–1.268)	
All-cause death or ischemic event				0.3196				0.5036
No prior OAC	2.35 (26)	3.19 (39)	0.733 (0.446–1.204)		7.93 (83)	7.29 (88)	1.041 (0.771–1.405)	
Prior NOAC	1.12 (7)	3.00 (18)	0.370 (0.155–0.886)		4.71 (29)	6.37 (37)	0.748 (0.463–1.207)	
Prior VKA	1.23 (7)	1.30 (6)	0.948 (0.319–2.821)		5.14 (29)	5.26 (24)	1.018 (0.595–1.741)	
Cardiovascular death				0.7627				0.7636
No prior OAC	0.72 (8)	0.99 (12)	0.736 (0.301–1.800)		3.02 (33)	2.83 (34)	1.072 (0.664–1.731)	
Prior NOAC	0.32 (2)	0.83 (5)	0.384 (0.075–1.979)		1.82 (11)	2.19 (13)	0.883 (0.403–1.934)	
Prior VKA	0.53 (3)	0.65 (3)	0.814 (0.164–4.035)		2.12 (12)	1.52 (7)	1.393 (0.548–3.538)	
Stroke				---				0.5352
No prior OAC	0.27 (3)	0.49 (6)	0.551 (0.138–2.205)		0.55 (6)	1.43 (17)	0.389 (0.154–0.988)	
Prior NOAC	0.00 (0)	0.34 (2)	---		0.66 (4)	1.27 (7)	0.546 (0.160–1.866)	
Prior VKA	0.18 (1)	0.22 (1)	0.814 (0.051–13.015)		0.54 (3)	0.44 (2)	1.222 (0.204–7.311)	
Myocardial infarction				0.1592				0.0136
No prior OAC	1.63 (18)	1.73 (21)	0.944 (0.503–1.772)		4.70 (48)	3.44 (41)	1.297 (0.855–1.967)	
Prior NOAC	0.48 (3)	2.01 (12)	0.238 (0.067–0.843)		1.47 (9)	3.89 (23)	0.356 (0.166–0.767)	
Prior VKA	0.53 (3)	0.65 (3)	0.814 (0.164–4.031)		2.53 (14)	3.34 (15)	0.816 (0.399–1.669)	

17 CI=confidence interval; CRNM=clinically relevant non-major; HR=hazard ratio; ISTH=International Society on Thrombosis and Haemostasis; KM=Kaplan-Meier;  
 18 NOAC=non-vitamin K antagonist oral anticoagulant; OAC=oral anticoagulant; VKA=vitamin K antagonist.

19

20 **eTable 2B. Association between Randomized Treatment (Aspirin vs. Placebo) and Endpoints by Prior Oral**  
 21 **Anticoagulant Status**

Endpoint	30 Days				180 Days			
	Aspirin KM % (events)	Placebo KM % (events)	HR (95% CI) Aspirin vs. Placebo	Interaction n p-value	Aspirin KM % (events)	Placebo KM % (events)	HR (95% CI) Aspirin vs. Placebo	Interaction p-value
ISTH major/CRNM bleeding				0.3208				0.9930
No prior OAC	7.82 (87)	3.99 (45)	1.976 (1.379–2.832)		17.29 (185)	9.45 (101)	1.882 (1.480– 2.393)	
Prior NOAC	6.65 (40)	3.44 (20)	1.949 (1.140–3.334)		16.02 (93)	8.89 (49)	1.927 (1.365– 2.720)	
Prior VKA	7.71 (38)	2.33 (12)	3.408 (1.781–6.522)		17.98 (85)	10.36 (51)	1.881 (1.330– 2.660)	
ISTH major bleeding				0.0893				0.5311
No prior OAC	2.70 (30)	0.98 (11)	2.766 (1.386–5.520)		5.49 (58)	2.98 (31)	1.931 (1.248– 2.986)	
Prior NOAC	1.01 (6)	1.21 (7)	0.826 (0.278–2.458)		3.92 (22)	3.14 (17)	1.250 (0.664– 2.354)	
Prior VKA	2.67 (13)	0.58 (3)	4.599 (1.311– 16.137)		5.76 (27)	3.49 (17)	1.798 (0.984– 3.284)	
Intracranial bleeding				---				0.4882
No prior OAC	0.18 (2)	0.18 (2)	1.007 (0.142–7.149)		0.48 (5)	0.38 (4)	1.285 (0.345– 4.786)	
Prior NOAC	0.00 (0)	0.00 (0)	---		0.37 (2)	0.39 (2)	0.962 (0.136– 6.831)	
Prior VKA	0.00 (0)	0.00 (0)	---		0.22 (1)	0.84 (4)	0.271 (0.030– 2.428)	
Definite/Probable stent thrombosis				0.8248				0.9394
No prior OAC	0.35 (4)	1.03 (12)	0.332 (0.107–1.030)		0.52 (6)	1.03 (12)	0.498 (0.187– 1.328)	
Prior NOAC	0.48 (3)	0.84 (5)	0.576 (0.138–2.411)		0.48 (3)	1.01 (6)	0.480 (0.120– 1.917)	
Prior VKA	0.20 (1)	0.38 (2)	0.524 (0.048–5.776)		0.40 (2)	0.57 (3)	0.699 (0.117– 4.181)	
All-cause death or rehospitalization				0.2021				0.4694
No prior OAC	11.72 (136)	9.79 (114)	1.202 (0.937–1.542)		26.99 (307)	23.88 (273)	1.157 (0.983– 1.362)	

Endpoint	30 Days			Interaction p-value	180 Days			Interaction p-value
	Aspirin KM % (events)	Placebo KM % (events)	HR (95% CI) Aspirin vs. Placebo		Aspirin KM % (events)	Placebo KM % (events)	HR (95% CI) Aspirin vs. Placebo	
Prior NOAC	9.78 (61)	10.51 (63)	0.926 (0.651–1.317)		27.68 (169)	27.52 (163)	0.991 (0.800–1.227)	
Prior VKA	9.75 (49)	6.45 (34)	1.533 (0.990–2.374)		24.58 (122)	24.61 (129)	1.021 (0.798–1.306)	
All-cause death or ischemic event				0.8331				0.8879
No prior OAC	2.15 (25)	3.43 (40)	0.623 (0.378–1.026)		6.93 (78)	8.23 (93)	0.840 (0.621–1.134)	
Prior NOAC	1.60 (10)	2.50 (15)	0.638 (0.287–1.420)		5.10 (31)	5.98 (35)	0.900 (0.560–1.449)	
Prior VKA	1.19 (6)	1.33 (7)	0.898 (0.302–2.672)		5.25 (26)	5.15 (27)	0.973 (0.571–1.659)	
Cardiovascular death				0.1992				0.7366
No prior OAC	0.52 (6)	1.20 (14)	0.428 (0.164–1.114)		2.64 (30)	3.21 (37)	0.814 (0.503–1.317)	
Prior NOAC	0.64 (4)	0.50 (3)	1.281 (0.287–5.724)		1.94 (12)	2.06 (12)	1.039 (0.474–2.277)	
Prior VKA	0.80 (4)	0.38 (2)	2.101 (0.385–11.472)		2.00 (10)	1.71 (9)	1.168 (0.475–2.875)	
Stroke				---				0.8133
No prior OAC	0.52 (6)	0.26 (3)	2.002 (0.501–8.006)		1.06 (12)	0.97 (11)	1.096 (0.484–2.485)	
Prior NOAC	0.00 (0)	0.34 (2)	---		0.82 (5)	1.10 (6)	0.800 (0.244–2.621)	
Prior VKA	0.20 (1)	0.19 (1)	1.051 (0.066–16.798)		0.61 (3)	0.39 (2)	1.580 (0.264–9.457)	
Myocardial infarction				0.6551				0.8970
No prior OAC	1.12 (13)	2.24 (26)	0.497 (0.255–0.966)		3.70 (41)	4.36 (48)	0.853 (0.562–1.295)	
Prior NOAC	0.97 (6)	1.51 (9)	0.639 (0.227–1.794)		2.12 (13)	3.22 (19)	0.705 (0.353–1.406)	
Prior VKA	0.20 (1)	0.95 (5)	0.210 (0.024–1.792)		2.70 (13)	3.08 (16)	0.799 (0.388–1.645)	

CI=confidence interval; CRNM=clinically relevant non-major; HR=hazard ratio; ISTH=International Society on Thrombosis and Haemostasis; KM=Kaplan-Meier; NOAC=non-vitamin K antagonist oral anticoagulant; OAC=oral anticoagulant; VKA=vitamin K antagonist.

22  
23  
24